BioScrip Inc. Reaches New 12-Month Low at $8.51 (BIOS)
BioScrip (NASDAQ:BIOS)’s share price reached a new 52-week low during mid-day trading on Tuesday, Stock Ratings Network.com reports. The stock traded as low as $8.51 and last traded at $8.77, with a volume of 6,652,098 shares traded. The stock had previously closed at $10.41.
BIOS has been the subject of a number of recent research reports. Analysts at Sidoti upgraded shares of BioScrip (NASDAQ:BIOS) from a “neutral” rating to a “buy” rating in a research note to investors on Wednesday, August 28th. Separately, analysts at Zacks reiterated a “neutral” rating on shares of BioScrip (NASDAQ:BIOS) in a research note to investors on Wednesday, August 14th. They now have a $15.00 price target on the stock. Finally, analysts at Zacks downgraded shares of BioScrip (NASDAQ:BIOS) from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, July 2nd. They now have a $17.00 price target on the stock.
Two analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $16.92.
BioScrip has a 52-week low of $8.81 and a 52-week high of $17.62. The stock’s 50-day moving average is $12.58 and its 200-day moving average is $13.90. The company’s market cap is $574.1 million.
BioScrip (NASDAQ:BIOS) last announced its earnings results on Wednesday, August 7th. The company reported $0.13 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.04 by $0.09. The company had revenue of $190.73 million for the quarter, compared to the consensus estimate of $206.47 million. During the same quarter in the prior year, the company posted ($0.07) earnings per share. The company’s quarterly revenue was up 22.3% on a year-over-year basis. On average, analysts predict that BioScrip will post $0.28 earnings per share for the current fiscal year.
BioScrip, Inc (NASDAQ:BIOS) is a provider of pharmacy and home health services, which partners with patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and the delivery of prescription medications and home health services.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.